Patent Extensions Cost US $3.5 Billion in Delayed Generic Savings
Written by
American Journal Managed Care
Published
0
comments
0
min
A new study finds that drugmakers’ use of overlapping patents delayed generic entry for 4 top-selling drugs, driving billions in excess spending.